Sukhdeep Kaur

Board Certifications: Hematology, Internal Medicine and Medical Oncology

Languages: English and Punjabi

Locations: Hackensack, NJ and Neptune, NJ

Sukhdeep Kaur, MD, is a hematologist-oncologist at John Theurer Cancer Center at Hackensack University Medical Center. She specializes in stem cell transplantation—including allogeneic transplants (from a donor) and autologous (“self”) transplants—for blood cancers and blood diseases. She also oversees the use of cellular therapies in patients, including CAR T-cell therapy—an innovative treatment which trains a patient’s white blood cells (called T cells) to find and destroy cancer cells. John Theurer Cancer Center was the first center in New Jersey to establish a CAR T-cell therapy program. Dr. Kaur received her medical degree from Ross University and completed her Internal Medicine residency at Drexel University College of Medicine, serving as Chief Resident in her final year. She then went on to complete a fellowship in hematology-oncology at Robert Wood Johnson University Hospital/Cancer Institute of New Jersey, where she was Chief Fellow. She is a member of the American Society of Hematology, American Society of Clinical Oncology, and American College of Physicians.

Education

  • Rose University School of Medicine

Residency

  • Drexel University College of Medicine Hahnemann University

Fellowships

  • Rutgers – New Jersey Medical School

Awards and honors

Awards and honors

  • Castle Connolly Regional Top Doctors: 1st Edition,
  • Jersey’s Best Magazine Top Doctors: 2018, 2019, 2020,
  • Jersey’s Best Top Doctors for Cancer: 2018
  • Exceptional Women In Medicine: 2020

Hospital Affiliations

  • Hackensack University Medical Center
  • Jersey Shore University Medical Center

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.